Aspire Pharma has acquired Charlwood Pharma, a privately owned company specialising in the research & development of niche generic medicines.
The acquisition marks the culmination of a multi-year collaboration between the two organisations.
Aspire Pharma chief executive Richard Condon said, “Under the terms of this agreement, Aspire will assume full ownership of all intellectual property, which reinforces our ambitions for international expansion.
“This acquisition further demonstrates Aspire’s commitment to delivering quality, affordable medicines that support the highest levels of patient care, while offering true value to healthcare systems throughout the world.”
Charlwood brings a robust pipeline of products spanning mental health, ear, nose and throat (ENT), cardiovascular and respiratory therapy areas.
Aspire has a presence in the specialty generics and medical device sectors. In 2021, Aspire was acquired by an affiliate of HIG Capital.
